**Supplemental Table S2.** Study treatment disposition (ITT population)

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Number of subjects**  **N (%)** | **Total**  **n=59** | **Part 1 afuresertib dose levels** | | | | | | **Part 2 group** | |
| **Total phase I n-29** | **Dose level 1**  **50mg afuresertib**  **n=4** | **Dose level 1.5**  **75mg afuresertib**  **n=4** | **Dose level 2**  **100mg afuresertib**  **n=6** | **Dose level 3**  **125mg afuresertib**  **n=12** | **Dose level 4**  **150mg afuresertib**  **n=3** | **Total Part 2**  **n=30** | **Cohort A**  **(treated at dose level 3) 125mg afuresertib**  **n=28** |
| P**rimary reason for treatment discontinuation** | 10 (16.9) | 4 (13.8) |  |  |  |  |  | 6  (20) | 6  (21.4) |
| Adverse Event | 2  (50) | 0 | 2  (33) | 0 | 0 |
| Progressive Disease (RECIST) | 35  (59.3) | 17 (58.6) | 2  (50) | 3  (75) | 1  (16.7) | 8  (66.7) | 3  (100) | 18  (60) | 6  (21.4) |
| Symptomatic deterioration/Clinical Progression | 8  (13.6) | 4 (13.8) | 0 | 1  (25) | 1  (16.7) | 2  (16.7) | 0 | 4  (13.3) | 4  (14.3) |
| Investigator Opinion | 1  (1.7) | 1  (3.4) | 0 | 0 | 0 | 1  (8.3) | 0 | 0 | 0 |
| Withdrawal of consent | 2  (3.4) | 2  (6.9) | 0 | 0 | 1  (16.7) | 1  (8.3) | 0 | 0 | 0 |
| Unknown | 2  (3.4) | 1  (3.4) | 0 | 0 | 1  (16.7) | 0 | 0 | 1  (3.3) | 0 |